NeoGenomics, Inc.

DB:NG9 Stock Report

Market Cap: €1.8b

NeoGenomics Valuation

Is NG9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NG9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NG9 (€14) is trading below our estimate of fair value (€63.95)

Significantly Below Fair Value: NG9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NG9?

Key metric: As NG9 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NG9. This is calculated by dividing NG9's market cap by their current revenue.
What is NG9's PS Ratio?
PS Ratio3.1x
SalesUS$644.12m
Market CapUS$1.93b

Price to Sales Ratio vs Peers

How does NG9's PS Ratio compare to its peers?

The above table shows the PS ratio for NG9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
SYAB SYNLAB
1x4.4%€2.5b
FME Fresenius Medical Care
0.6x3.8%€12.2b
FRE Fresenius SE KGaA
0.8x3.6%€18.5b
V3V VITA 34
0.9x3.1%€74.6m
NG9 NeoGenomics
3.1x10.1%€1.9b

Price-To-Sales vs Peers: NG9 is expensive based on its Price-To-Sales Ratio (3.1x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does NG9's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.1xn/aUS$5.15m
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.89m
No more companies available in this PS range
NG9 3.1xIndustry Avg. 0.6xNo. of Companies4PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NG9 is expensive based on its Price-To-Sales Ratio (3.1x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is NG9's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NG9 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.1x
Fair PS Ratio1.6x

Price-To-Sales vs Fair Ratio: NG9 is expensive based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NG9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€14.00
€19.63
+40.2%
17.2%€28.16€16.89n/a11
Nov ’25€12.50
€19.31
+54.5%
17.2%€27.71€16.62n/a11
Oct ’25€13.10
€19.03
+45.3%
16.8%€26.96€16.17n/a11
Sep ’25€14.70
€19.33
+31.5%
16.8%€27.38€16.43n/a11
Aug ’25€16.30
€19.48
+19.5%
17.0%€27.71€16.62n/a11
Jul ’25€12.80
€19.07
+49.0%
16.1%€26.10€15.85n/a11
Jun ’25€12.90
€19.07
+47.8%
16.1%€26.10€15.85n/a11
May ’25€14.70
€19.30
+31.3%
16.3%€26.19€15.90n/a11
Apr ’25€14.00
€19.86
+41.8%
17.1%€27.65€16.59n/a11
Mar ’25€14.40
€19.86
+37.9%
17.1%€27.65€16.59n/a11
Feb ’25€14.50
€18.55
+27.9%
15.4%€24.01€15.70n/a11
Jan ’25€15.30
€18.20
+18.9%
15.4%€23.55€15.40n/a11
Dec ’24€16.60
€19.61
+18.1%
20.2%€28.01€14.94n/a11
Nov ’24€13.20
€19.05
+44.3%
18.8%€24.55€14.16€12.5011
Oct ’24€11.80
€19.30
+63.5%
15.0%€23.69€15.49€13.1011
Sep ’24€13.80
€19.30
+39.8%
15.0%€23.69€15.49€14.7011
Aug ’24€15.70
€19.56
+24.6%
12.7%€23.50€15.37€16.3011
Jul ’24€14.60
€20.18
+38.2%
14.5%€25.79€15.66€12.8011
Jun ’24€16.00
€20.18
+26.1%
14.5%€25.79€15.66€12.9011
May ’24€12.90
€18.41
+42.7%
14.2%€23.83€15.58€14.7011
Apr ’24€15.96
€18.98
+18.9%
13.7%€24.45€15.99€14.0011
Mar ’24€15.72
€18.96
+20.6%
14.1%€24.65€16.11€14.4011
Feb ’24€11.53
€14.29
+24.0%
27.2%€23.67€9.10€14.5010
Jan ’24€8.73
€15.59
+78.6%
27.7%€25.16€9.68€15.309
Dec ’23€10.59
€15.59
+47.2%
27.7%€25.16€9.68€16.609
Nov ’23€7.68
€16.84
+119.4%
27.4%€26.09€10.04€13.209

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Ship Healthcare Holdings

JP¥198.5b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.50

7D

-0.8%

1Y

-3.1%

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-6.2%

1Y

-37.3%

LNA Santé

€241.3m

Engages in the management and operation of health establishments.

2N3

€22.65

7D

-9.4%

1Y

10.2%